Study duration per participant is approximately 8 weeks including a 21-day screening and baseline phase, a 4-day treatment phase and a 28-day follow up period after dosing.
Primary Objective:~To assess the safety and tolerability of SAR441255 after ascending single subcutaneous (SC) doses~Secondary Objectives:~To assess the pharmacokinetic parameters of SAR441255 in plasma after ascending single SC doses~To assess the pharmacodynamic effects on glycemic parameters (fasting and postprandial glucose, C-peptide and insulin)